Neurobehavioral effects of levetiracetam in brain tumor related epilepsy

Frontiers in Neurology

Volumn 4 JUL, Issue , 2013, Pages

  Bernett, Abigail ^a   Phenis, Richard ^a   Fonkem, Ekokobe ^a,b   Aceves, Jose ^a,b   Kirmani, Batool ^a,b   Cruz Laureano, Daniel ^a,b  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Brain tumors; Levetiracetam; Neurobehavioral; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TEMOZOLOMIDE; TOPIRAMATE;

ADD ON THERAPY; AGGRESSION; ARTICLE; ATAXIA; BEHAVIOR CHANGE; BLURRED VISION; BRAIN TUMOR; COGNITIVE DEFECT; DEPRESSION; DIARRHEA; DIPLOPIA; DISEASE ASSOCIATION; DISEASE MODEL; DIZZINESS; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPILEPSY; FATIGUE; GLIOBLASTOMA; HUMAN; IRRITABILITY; LEUKOPENIA; LIVER TOXICITY; MONOTHERAPY; MORBIDITY; NAUSEA AND VOMITING; NONHUMAN; PARESTHESIA; PERIARTHRITIS; PSYCHOSIS; QUALITY OF LIFE; RESTLESSNESS; SIDE EFFECT; SOMNOLENCE; VISUAL HALLUCINATION; WEIGHT REDUCTION;

EID: 84883524023     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2013.00099     Document Type: Article

References (44)

1. Panayiotopoulos CP. A Clinical Guide to Epileptic Syndromes and their Treatment. 2nd ed. London: Springer (2010).
2. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia (2007) 48:1223-44. doi:10.1111/j.1528-1167.2007.01041.x
3. Loring DW, Marino S, Meador KJ. Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychol Rev (2007) 17:413-25. doi:10.1007/s11065-007-9043-9
4. Schmitz B. Effects of antiepileptic drugs on mood and behavior. Epilepsia (2006) 47:28-33. doi:10.1111/j.1528-1167.2006.00684.x
5. Perucca P, Gilliam F. Adverse effects of antiepileptic drugs. Lancet Neurol (2012) 11:792-802. doi:10.1016/S1474-4422(12)70153-9
6. Lynam LM, Lyons MK, Drazkowski JF, Sirven JI, Noe KH, Zimmerman RS, et al. Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. Clin Neurol Neurosurg (2007) 109:634-8. doi:10.1016/j.clineuro.2007.05.017
7. Hildebrand J, Lecaille C, Perennes J, Delattre JY. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology (2005) 65:212-5. doi:10.1212/01.wnl.0000168903.09277.8f
8. Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2000) 54:1886-93. doi:10.1212/WNL.54.10.1886
9. Lieu AS, Howng SL. Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. Epilepsy Res (2000) 38:45-52. doi:10.1016/S0920-1211(99)00066-2
10. Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B. The course of seizure disorders in patients with malignant gliomas. Arch Neurol (1995) 52:717-24. doi:10.1001/archneur.1995.00540310091021
11. Rosetti AO, Stupp R. Epilepsy in brain tumor patients. Curr Opin Neurol (2010) 23:603-9. doi:10.1097/WCO.0b013e32833e996c
12. de Groot M, Reijneveld JC, Aronica E, Heimans JJ. Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment. Brain (2012) 135:1002-16. doi:10.1093/brain/awr310
13. van Breemen MSM, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol (2007) 6:421-30. doi:10.1016/S1474-4422(07)70103-5
14. Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY. Medical management of brain tumor patients. Neurol Clin (2007) 25:1035-71. doi:10.1016/j.ncl.2007.07.015
15. Maschio M, Dinapoli L. Patients with brain tumor-related epilepsy. J Neurooncol (2012) 109:1-6. doi:10.1007/s11060-012-0867-7
16. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A (2004) 101:9861-6. doi:10.1073/pnas.0308208101
17. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther (2000) 85:77-85. doi:10.1016/S0163-7258(99)00052-2
18. Landmark CJ, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother (2010) 10:119-40. doi:10.1586/ern.09.136
19. Bobustuc CG, Baker CH, Limaye A, Jenkins WD, Pearl G, Avgeropoulos NG, et al. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol (2010) 12:917-27. doi:10.1093/neuonc/noq044
20. de Groot M, Aronica E, Heimans JJ, Reijneveld JC. Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. Neurology (2011) 77:532-9. doi:10.1212/WNL.0b013e318228c110
21. Maschio M, Dinapoli L, Gomellini S, Ferraresi V, Sperati F, Vidiri A, et al. Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy. J Neurooncol (2010) 98:109-16. doi:10.1007/s11060-009-0069-0
22. van Breemen MSM, Rijsman RM, Taphoorn MJB, Walchenbach R, Zwinkels H, Vecht CJ. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol (2009) 256:1519-26. doi:10.1007/s00415-009-5156-9
23. Milligan TA, Hurwitz S, Bromfield EB. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology (2008) 71:665-9. doi:10.1212/01.wnl.0000324624.52935.46
24. Lim DA, Tarapore P, Chang E, Burt M, Chakalian L, Barbaro N, et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J Neurooncol (2009) 93:349-54. doi:10.1007/s11060-008-9781-4
25. Lyseng-Williamson KA. Levetiracetam: a review of its use in epilepsy. Drugs (2011) 71:489-514.
26. French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res (2001) 47:77-90. doi:10.1016/S0920-1211(01)00296-0
27. Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ. Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav (2007) 10:105-10. doi:10.1016/j.yebeh.2006.08.008
28. Helmstaedter C, Fritz NE, Kockelmann E, Kosanetzky N, Elger CE. Positive and negative psychotropic effects of levetiracetam. Epilepsy Behav (2008) 13:535-41. doi:10.1016/j.yebeh.2008.05.012
29. Dinkelacker V, Dietl T, Widman G, Lengler U, Elger CE. Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epilepsy Behav (2003) 4:537-47. doi:10.1016/j.yebeh.2003.07.008
30. Mula M, Bell GS, Sander JW. Suicidality in epilepsy and possible effects of antiepileptic drugs. Curr Neurol Neurosci Rep (2010) 10:327-32. doi:10.1007/s11910-010-0117-3
31. Merrell RT, Anderson KS, Meyer FB, Lachance DH. Seizures in patients with glioma treated with phenytoin and levetiracetam. J Neurosurg (2010) 113:1176-81. doi:10.3171/2010.5.JNS091367
32. Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol (2006) 78:99-102. doi:10.1007/s11060-005-9070-4
33. Newton HB, Dalton J, Goldlust S, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. J Neurooncol (2007) 84:293-6. doi:10.1007/s11060-007-9373-8
34. Rosati A, Buttolo L, Stefini R, Todeschini A, Cenzato M, Padovani A. Efficacy and safety of levetiracetam in patients with glioma. Arch Neurol (2010) 67:343-6. doi:10.1001/archneurol.2009.335
35. Wagner GL, Wilms EB, Van Donselaar CA, Vecht CJ. Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure (2003) 12:585-6. doi:10.1016/S1059-1311(03)00096-7
36. Zachenhofer I, Donat M, Oberndorfer S, Roessler K. Perioperative levetiracetam for prevention of seizures in supratentorial brain tumor surgery. J Neurooncol (2011) 101:101-6. doi:10.1007/s11060-010-0235-4
37. Usery JB, Michael LM II, Sills AK, Finch CK. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neurooncol (2010) 99:251-60. doi:10.1007/s11060-010-0126-8
38. Brandt J, Spencer M, Folstein M. The telephone interview for cognitive status. Neuropsychiatry Neuropsychol Behav Neurol (1988) 1:111-7.
39. Dinapoli L, Maschio M, Jandolo B, Fabi A, Pace A, Sperati F, et al. Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. Neurol Sci (2009) 30:353-9. doi:10.1007/s10072-009-0087-x
40. Brown PD, Buckner JC, O'Fallon JR, Iturria NL, Brown CA, O'Neill BP, et al. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol (2003) 21:2519-24. doi:10.1200/JCO.2003.04.172
41. Karnofsky DA, Burchenal JH, Armistead GC, Southam CM, Bernstein JL, Craver LF, et al. Triethylene melamine in the treatment of neoplastic disease. Arch Intern Med (1951) 87:477-516. doi:10.1001/archinte.1951.03810040002001
42. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md State Med J (1965) 14:61-5.
43. Maschio M, Dinapoli L, Sperati F, Pace A, Fabi A, Vidiri A, et al. Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. J Neurooncol (2011) 104:205-14. doi:10.1007/s11060-010-0460-x
44. Maschio M, Alabani F, Baruzzi A, Zarabla A, Dinapoli L, Pace A, et al. Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol (2006) 80:97-100. doi:10.1007/s11060-006-9162-9